DOCSLIB.ORG

Genetic Disruption of Oncogenic Kras Sensitizes Lung Cancer Cells to Fas Receptor-Mediated Apoptosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Disruption of Oncogenic Kras Sensitizes Lung Cancer Cells to Fas Receptor-Mediated Apoptosis Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis Haiwei Moua,1, Jill Mooreb,1, Sunil K. Maloniac,1, Yingxiang Lib,d, Deniz M. Ozataa, Soren Hougha, Chun-Qing Songa, Jordan L. Smitha, Andrew Fischere, Zhiping Wengb, Michael R. Greenc,f,2, and Wen Xuea,c,g,2 aRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605; bProgram in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA 01605; cDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605; dDepartment of Bioinformatics, School of Life Science and Technology, Tongji University, Shanghai 200092, People’s Republic of China; eDepartment of Pathology, University of Massachusetts Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA 01605; fHoward Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01604; and gProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605 Contributed by Michael R. Green, December 28, 2016 (sent for review July 14, 2016; reviewed by Michael T. Hemann and Andrea Ventura) Genetic lesions that activate KRAS account for ∼30% of the 1.6 million Because shRNAs targeting Kras do not completely eliminate annual cases of lung cancer. Despite clinical need, KRAS is still undrug- Kras expression, residual Kras in cells could contribute to Kras- gable using traditional small-molecule drugs/inhibitors. When onco- independent tumor growth. The best way to rule out this possibility genic Kras is suppressed by RNA interference, tumors initially regress is to genetically delete Kras altogether. Unfortunately, the Kras Kras but eventually recur and proliferate despite suppression of . Here, knockout mouse is embryonically lethal (17), and genetic disruption Kras we show that tumor cells can survive knockout of oncogenic , of KRAS—or other oncogenes—in human cells remains a chal- indicating the existence of Kras-independent survival pathways. Thus, lenge due to the low efficiency of homologous recombination using even if clinical KRAS inhibitors were available, resistance would re- main an obstacle to treatment. Kras-independent cancer cells exhibit traditional gene-targeting technology. We recently showed that decreased colony formation in vitro but retain the ability to form CRISPR (18) can be used to efficiently and specifically edit cancer tumors in mice. Comparing the transcriptomes of oncogenic Kras cells genes in adult mice in a fraction of the time and cost of traditional and Kras knockout cells, we identified 603 genes that were specifi- mouse models (19–21). CRISPR therefore provides a flexible ge- CELL BIOLOGY cally up-regulated in Kras knockout cells, including the Fas gene, netic system to manipulate the function of cancer genes (22, 23). which encodes a cell surface death receptor involved in physiological Previous work has shown that oncogenic KRAS epigenetically regulation of apoptosis. Antibodies recognizing Fas receptor effi- silences Fas expression (24, 25). In addition, RAS directs epige- ciently induced apoptosis of Kras knockout cells but not oncogenic netic silencing of Fas through a highly ordered pathway that cul- Kras-expressing cells. Increased Fas expression in Kras knockout cells minates in methylation of the Fas promoter (26, 27). It remains was attributed to decreased association of repressive epigenetic unexplored whether Fas can be restored by genetic inactivation of Fas marks at the promoter. Concordant with this observation, treat- oncogenic RAS. ing oncogenic Kras cells with histone deacetylase inhibitor and Fas- activating antibody efficiently induced apoptosis, thus bypassing the need to inhibit Kras. Our results suggest that activation of Significance Fas could be exploited as an Achilles’ heel in tumors initiated by oncogenic Kras. Oncogenic KRAS underlies 30–90% of lung, colon, and pancreatic cancers, but despite more than 30 y of research, clinical inhibitors Kras | lung cancer | Fas | apoptosis of KRAS—and potential resistance mechanisms—remain elusive. Using CRISPR-mediated genome editing of oncogenic Kras,we show that some lung cancer cells can survive Kras knockout, ung cancer is a leading cause of cancer death, accounting for indicating the existence of mechanisms that allow tumors to ∼1.3 million deaths worldwide each year (1). Non–small-cell L escape Kras oncogene addiction. We identify genes highly lung cancer (NSCLC), the most common subtype, is associated expressed in Kras knockout cells, including the Fas receptor with frequent mutations in KRAS (∼30%). KRAS is also frequently gene. Antibodies that activate Fas receptor selectively induced mutated in other tumor types, including pancreatic (>90%) and apoptosis in Kras-independent lung cancer cells, suggesting a colon (∼30%) cancer (2). Although various pharmacological in- potential strategy for combinatorial therapies against Kras- hibitors are being developed for RAS, especially for the mutant driven tumors. These findings have direct translational implica- KRASG12C (3–5), these small molecules have not been tested in tions for the treatment of lung cancer and other KRAS mutant the clinic (6, 7). As a result, advanced oncogenic KRAS lung cancer types. cancers are usually treated with conventional therapy such as ra- diation and chemotherapy, often with limited success (1, 8). Author contributions: H.M., J.M., S.K.M., Z.W., M.R.G., and W.X. designed research; H.M., Controlled expression of oncogenic RAS cDNA in mouse S.K.M., D.M.O., S.H., C.-Q.S., and J.L.S. performed research; H.M., S.K.M., Y.L., D.M.O., S.H., models of melanoma, lung, breast, and pancreatic cancer has C.-Q.S., J.L.S., and A.F. analyzed data; J.M., Y.L., and Z.W. analyzed RNA-seq and TCGA shown that the withdrawal of oncogenic RAS results in complete data; A.F. analyzed tumor pathology; and H.M., J.M., S.K.M., Z.W., M.R.G., and W.X. tumor regression (9–11). This phenomenon, known as “oncogene wrote the paper. – addiction,” suggests that oncogenic KRAS alleles (e.g., KRASG12D) Reviewers: M.T.H., Massachusetts Institute of Technology; and A.V., Memorial Sloan Kettering Cancer Center. not only initiate tumorigenesis but also play a crucial role in tumor The authors declare no conflict of interest. maintenance. To recapitulate KRAS oncogene addiction in a mouse model of lung cancer, we developed a conditional Kras Data deposition: The deep-sequencing data reported in this paper have been deposited in G12D/+ −/− the National Center for Biotechnology Information BioProject database (accession no. shRNA system (shKras) to knock down Kras in Kras ;p53 PRJNA356881). – (KP) cell lines derived from a mouse lung tumor (12 14). When 1H.M., J.M., and S.K.M. contributed equally to this work. we orthotopically transplanted shKras KP cells into immuno- 2To whom correspondence may be addressed. Email: [email protected] or compromised mice, we found that Kras-driven lung tumors can [email protected]. escape oncogene addiction and become independent of Kras This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. signaling (termed Kras independence) (15, 16). 1073/pnas.1620861114/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1620861114 PNAS Early Edition | 1of6 Downloaded by guest on September 27, 2021 − − Here, we use CRISPR to establish viable Kras knockout (Kras / ) G12D/+ lung cancer cell lines from parental oncogenic Kras (Kras ) cells. While investigating the mechanism of Kras-independent tu- morigenesis in this model, we identified Fas among the genes most highly regulated by Kras. Fas (also known as CD95, APO-1, and TNFRSF6) encodes a cell surface death receptor that triggers apoptosis upon binding by its cognate ligand, Fas ligand (FasL) (or CD95L), and plays critical roles in the immune elimination of cancer cells (28, 29). In both mouse and human lung cancer cells, genetic disruption of Kras elevated Fas expression on the cell sur- face and increased sensitivity to Fas-mediated apoptosis, thereby demonstrating a selective vulnerability of Kras-independent cells. Consistent with previous work showing that oncogenic KRAS epi- genetically silences Fas expression (24, 25), we show that Fas is − − activated in Kras / cells by loss of both Dnmt1 and Ezh2 re- cruitment and repressive epigenetic marks of the Fas promoter. + Remarkably, treatment of parental KrasG12D/ cells with pharma- cological histone deacetylase (HDAC) inhibitors not only increased Fas levels but also sensitized cells to Fas-mediated apoptosis. These results suggest a combinatorial strategies for targeted elimination of Kras-independent and oncogenic Kras lung cancer cells. Results Kras Knockout Murine Lung Cancer Cells Are Viable and Can Form Fig. 1. CRISPR-mediated Kras knockout in Kras-driven mouse lung adeno- Tumors in Mice. Our previous study showed that shRNAs target- carcinoma cells. (A) Schematic diagram of CRISPR sgRNA design targeting exon G12D/+ “ ” ing Kras do not completely eliminate Kras in cells (16), hence the 2 of the mutant Kras allele (Kras ). Codon 12 is underlined. GAT encodes G12D mutation. Red arrowhead indicates the Cas9 cutting site. (B) residual Kras might contribute to Kras independence. We there- Immunoblot demonstrating total Kras protein levels in KP1 and KP2 clone fore used CRISPR-based method to genetically disrupt oncogenic pairs. Each pair included two clones: one parental (KP1/KP2) and one Kras G12D/+ −/− Kras in two independent mouse Kras ;p53 lung cancer knockout (KP1 clone/KP2 clone). Hsp90 was used as a loading control. (C) cell lines (termed KP1 and KP2) (30–32). Lentiviral vector Deep-sequencing analysis showing small deletions induced by CRISPR in a (lentiCRISPR) with puromycin selection marker, as described representative clone. (Upper) Representative IGV plots. Black bars denote previously (33), was used to deliver Cas9 and a sgRNA targeting deletions (purple circle). The red “T” is the G12D mutation. The HindIII site G12D G12D/+ Kras (sgKras) into the target cells (Fig. 1A). The puromycin- (“C” SNP) was engineered in the original Kras mouse model.
Load more

Recommended publications
  • The TNF and TNF Receptor Review Superfamilies: Integrating Mammalian Biology
    Cell, Vol. 104, 487±501, February 23, 2001, Copyright 2001 by Cell Press The TNF and TNF Receptor Review Superfamilies: Integrating Mammalian Biology Richard M. Locksley,*²³k Nigel Killeen,²k The receptors and ligands in this superfamily have and Michael J. Lenardo§k unique structural attributes that couple them directly to *Department of Medicine signaling pathways for cell proliferation, survival, and ² Department of Microbiology and Immunology differentiation. Thus, they have assumed prominent ³ Howard Hughes Medical Institute roles in the generation of tissues and transient microen- University of California, San Francisco vironments. Most TNF/TNFR SFPs are expressed in the San Francisco, California 94143 immune system, where their rapid and potent signaling § Laboratory of Immunology capabilities are crucial in coordinating the proliferation National Institute of Allergy and Infectious Diseases and protective functions of pathogen-reactive cells. National Institutes of Health Here, we review the organization of the TNF/TNFR SF Bethesda, Maryland 20892 and how these proteins have been adapted for pro- cesses as seemingly disparate as host defense and or- ganogenesis. In interpreting this large and highly active Introduction area of research, we have focused on common themes that unite the actions of these genes in different tissues. Three decades ago, lymphotoxin (LT) and tumor necro- We also discuss the evolutionary success of this super- sis factor (TNF) were identified as products of lympho- familyÐsuccess that we infer from its expansion across cytes and macrophages that caused the lysis of certain the mammalian genome and from its many indispens- types of cells, especially tumor cells (Granger et al., able roles in mammalian biology.
    [Show full text]
  • Pro- and Anti-Apoptotic CD95 Signaling in T Cells Maren Paulsen* and Ottmar Janssen
    Paulsen and Janssen Cell Communication and Signaling 2011, 9:7 http://www.biosignaling.com/content/9/1/7 DEBATE Open Access Pro- and anti-apoptotic CD95 signaling in T cells Maren Paulsen* and Ottmar Janssen Abstract The TNF receptor superfamily member CD95 (Fas, APO-1, TNFRSF6) is known as the prototypic death receptor in and outside the immune system. In fact, many mechanisms involved in apoptotic signaling cascades were solved by addressing consequences and pathways initiated by CD95 ligation in activated T cells or other “CD95-sensitive” cell populations. As an example, the binding of the inducible CD95 ligand (CD95L) to CD95 on activated T lymphocytes results in apoptotic cell death. This activation-induced cell death was implicated in the control of immune cell homeostasis and immune response termination. Over the past years, however, it became evident that CD95 acts as a dual function receptor that also exerts anti-apoptotic effects depending on the cellular context. Early observations of a potential non-apoptotic role of CD95 in the growth control of resting T cells were recently reconsidered and revealed quite unexpected findings regarding the costimulatory capacity of CD95 for primary T cell activation. It turned out that CD95 engagement modulates TCR/CD3-driven signal initiation in a dose- dependent manner. High doses of immobilized CD95 agonists or cellular CD95L almost completely silence T cells by blocking early TCR-induced signaling events. In contrast, under otherwise unchanged conditions, lower amounts of the same agonists dramatically augment TCR/CD3-driven activation and proliferation. In the present overview, we summarize these recent findings with a focus on the costimulatory capacity of CD95 in primary T cells and discuss potential implications for the T cell compartment and the interplay between T cells and CD95L-expressing cells including antigen-presenting cells.
    [Show full text]
  • A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-Cell Immunotherapy
    Published OnlineFirst December 17, 2020; DOI: 10.1158/2159-8290.CD-20-0756 RESEARCH BRIEF A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy Ranjan Upadhyay1,2,3, Jonathan A. Boiarsky1,2,3, Gvantsa Pantsulaia1,2,3, Judit Svensson-Arvelund1,2,3, Matthew J. Lin1,2,3, Aleksandra Wroblewska2,3,4, Sherry Bhalla3,4, Nathalie Scholler5, Adrian Bot5, John M. Rossi5, Norah Sadek1,2,3, Samir Parekh1,2,3, Alessandro Lagana4, Alessia Baccarini2,3,4, Miriam Merad2,3,6, Brian D. Brown2,3,4, and Joshua D. Brody1,2,3 ABSTRACT T cell–based therapies have induced cancer remissions, though most tumors ulti- mately progress, reflecting inherent or acquired resistance including antigen Bianca Dunn by Illustration escape. Better understanding of how T cells eliminate tumors will help decipher resistance mecha- nisms. We used a CRISPR/Cas9 screen and identified a necessary role for Fas–FasL in antigen-specific T-cell killing. We also found that Fas–FasL mediated off-target “bystander” killing of antigen-negative tumor cells. This localized bystander cytotoxicity enhanced clearance of antigen-heterogeneous tumors in vivo, a finding that has not been shown previously. Fas-mediated on-target and bystander killing was reproduced in chimeric antigen receptor (CAR-T) and bispecific antibody T-cell models and was augmented by inhibiting regulators of Fas signaling. Tumoral FAS expression alone predicted survival of CAR-T–treated patients in a large clinical trial (NCT02348216). These data suggest strate- gies to prevent immune escape by targeting both the antigen expression of most tumor cells and the geography of antigen-loss variants.
    [Show full text]
  • CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30 And
    Published OnlineFirst August 7, 2018; DOI: 10.1158/2326-6066.CIR-18-0065 Research Article Cancer Immunology Research CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30þ and CD30– Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions Lee K. Hong1, Yuhui Chen2, Christof C. Smith1, Stephanie A. Montgomery3, Benjamin G. Vincent2, Gianpietro Dotti1,2, and Barbara Savoldo2,4 Abstract Tumor antigen heterogeneity limits success of chimeric (NSG) mouse model of metastatic EC. We observed that CD30. þ antigen receptor (CAR) T-cell therapies. Embryonal carcino- CAR T cells, while targeting CD30 EC tumor cells through mas (EC) and mixed testicular germ cell tumors (TGCT) the CAR (i.e., antigen-dependent targeting), also eliminated – containing EC, which are the most aggressive TGCT subtypes, surrounding CD30 EC cells in an antigen-independent man- are useful for dissecting this issue as ECs express the CD30 ner, via a cell–cell contact-dependent Fas/FasL interaction. In – þ – antigen but also contain CD30 /dim cells. We found that CD30- addition, ectopic Fas (CD95) expression in CD30 Fas EC was redirected CAR T cells (CD30.CAR T cells) exhibit antitumor sufficient to improve CD30.CAR T-cell antitumor activity. activity in vitro against the human EC cell lines Tera-1, Tera-2, Overall, these data suggest that CD30.CAR T cells might be and NCCIT and putative EC stem cells identified by Hoechst useful as an immunotherapy for ECs. Additionally, Fas/FasL dye staining. Cytolytic activity of CD30.CAR T cells was com- interaction between tumor cells and CAR T cells can be plemented by their sustained proliferation and proinflamma- exploited to reduce tumor escape due to heterogeneous antigen tory cytokine production.
    [Show full text]
  • Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy
    Hindawi Publishing Corporation ISRN Oncology Volume 2013, Article ID 371854, 25 pages http://dx.doi.org/10.1155/2013/371854 Review Article Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy Edwin Bremer Department of Surgery, Translational Surgical Oncology, University Medical Center Groningen, University of Groningen, 9713GZ Groningen, The Netherlands Correspondence should be addressed to Edwin Bremer; [email protected] Received 10 April 2013; Accepted 11 May 2013 AcademicEditors:H.Al-Ali,J.Bentel,D.Canuti,L.Mutti,andR.V.Sionov Copyright © 2013 Edwin Bremer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The tumor necrosis factor (TNF) ligand and cognate TNF receptor superfamilies constitute an important regulatory axis that is pivotal for immune homeostasis and correct execution of immune responses. TNF ligands and receptors are involved in diverse biological processes ranging from the selective induction of cell death in potentially dangerous and superfluous cells to providing costimulatory signals that help mount an effective immune response. This diverse and important regulatory role in immunity has sparked great interest in the development of TNFL/TNFR-targeted cancer immunotherapeutics. In this review, I will discuss the biology of the most prominent proapoptotic and co-stimulatory TNF ligands and review their current status in cancer immunotherapy. 1. Introduction ligand/receptor interaction induces formation of a Death Inducing Signaling Complex (DISC) to the cytoplasmic DD The tumor necrosis factor (TNF) superfamily is comprised [3]. This DISC comprises the adaptor protein Fas-associated of 27 ligands that all share the hallmark extracellular TNF death domain (FADD) and an inactive proform of the homology domain (THD) [1].
    [Show full text]
  • Activation Cell Homeostasis in Chronic Immune Cutting Edge
    Cutting Edge: CD95 Maintains Effector T Cell Homeostasis in Chronic Immune Activation This information is current as Ramon Arens, Paul A. Baars, Margot Jak, Kiki Tesselaar, of September 24, 2021. Martin van der Valk, Marinus H. J. van Oers and René A. W. van Lier J Immunol 2005; 174:5915-5920; ; doi: 10.4049/jimmunol.174.10.5915 http://www.jimmunol.org/content/174/10/5915 Downloaded from References This article cites 30 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/174/10/5915.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY CUTTING EDGE Cutting Edge: CD95 Maintains Effector T Cell Homeostasis in Chronic Immune Activation Ramon Arens,1*†‡ Paul A. Baars,* Margot Jak,* Kiki Tesselaar,* Martin van der Valk,§ Marinus H.
    [Show full text]
  • A Small Peptide Antagonist of the Fas Receptor Inhibits Neuroinflammation
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2019-09-30 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma Anitha Krishnan Harvard Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Amino Acids, Peptides, and Proteins Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell Biology Commons, Eye Diseases Commons, Nervous System Commons, Neuroscience and Neurobiology Commons, and the Ophthalmology Commons Repository Citation Krishnan A, Kocab AJ, Zacks DN, Marshak-Rothstein A, Gregory-Ksander M. (2019). A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma. Open Access Articles. https://doi.org/ 10.1186/s12974-019-1576-3. Retrieved from https://escholarship.umassmed.edu/oapubs/3987 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Krishnan et al. Journal of Neuroinflammation (2019) 16:184 https://doi.org/10.1186/s12974-019-1576-3 RESEARCH Open Access A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma Anitha Krishnan1, Andrew J.
    [Show full text]
  • Differential Regulation and Function of Fas Expression on Glial Cells Sung Joong Lee, Tong Zhou, Chulhee Choi, Zheng Wang and Etty N
    Differential Regulation and Function of Fas Expression on Glial Cells Sung Joong Lee, Tong Zhou, Chulhee Choi, Zheng Wang and Etty N. Benveniste This information is current as of September 28, 2021. J Immunol 2000; 164:1277-1285; ; doi: 10.4049/jimmunol.164.3.1277 http://www.jimmunol.org/content/164/3/1277 Downloaded from References This article cites 70 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/164/3/1277.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 28, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Differential Regulation and Function of Fas Expression on Glial Cells1 Sung Joong Lee,* Tong Zhou,† Chulhee Choi,* Zheng Wang,† and Etty N. Benveniste2* Fas/Apo-1 is a member of the TNF receptor superfamily that signals apoptotic cell death in susceptible target cells. Fas or Fas ligand (FasL)-deficient mice are relatively resistant to the induction of experimental allergic encephalomyelitis, implying the involvement of Fas/FasL in this disease process.
    [Show full text]
  • Human T Cells − CD27 + CD45RA + Effector-Type CD8 Activation
    Cytolytic Mechanisms and Expression of Activation-Regulating Receptors on Effector-Type CD8+CD45RA+CD27− Human T Cells This information is current as of September 29, 2021. Paul A. Baars, Laura M. Ribeiro do Couto, Jeanette H. W. Leusen, Berend Hooibrink, Taco W. Kuijpers, Susanne M. A. Lens and René A. W. van Lier J Immunol 2000; 165:1910-1917; ; doi: 10.4049/jimmunol.165.4.1910 Downloaded from http://www.jimmunol.org/content/165/4/1910 References This article cites 45 articles, 19 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/165/4/1910.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 29, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Cytolytic Mechanisms and Expression of Activation-Regulating Receptors on Effector-Type CD8؉CD45RA؉CD27؊ Human T Cells Paul A. Baars,1* Laura M.
    [Show full text]
  • 8 Death Receptor Mutations
    Chapter 8 / Death Receptor Mutations 149 8 Death Receptor Mutations Sug Hyung Lee, MD, PhD, Nam Jin Yoo, MD, PhD, and Jung Young Lee, MD, PhD, SUMMARY It is generally believed that human cancers may arise as the result of an accumulation of mutations in genes and subsequent clonal selection of variant progeny with increas- ingly aggressive behaviors. Also, among the remarkable advances in our understanding in cancer biology is the realization that apoptosis has a profound effect on the malignant phenotypes. Along with these, compelling evidence indicates that somatic mutations in the genes encoding apoptosis-related proteins contribute to either development or pro- gression of human cancers. In this chapter, we present an overview of the death receptor pathway and its dysregulation in cancers. We then review the current knowledge of death receptor mutations that have been detected in humans. INTRODUCTION Programmed cell death through apoptosis plays a fundamental role in a variety of physiological processes, and its deregulation contributes to many diseases, including autoimmunity, cancer, acquisition of drug resistance in tumors, stroke, progression of some degenerative diseases, and acquired immunodeficiency syndrome (AIDS) (1–4). Apoptosis is an active cell-suicide process executed by a cascade of molecular events involving a number of membrane receptors and cytoplasmic proteins (1–4). Although many pathways for activating caspases may exist, only two, the intrinsic pathway and the extrinsic pathway, have been demonstrated in detail (3). The extrinsic pathway can be induced by members of the tumor necrosis factor (TNF) receptor family, such as TNF receptor 1 (TNFR1) and Fas (5–7).
    [Show full text]
  • Death Receptors Couple to Both Cell Proliferation and Apoptosis
    Death receptors couple to both cell proliferation and apoptosis Ralph C. Budd J Clin Invest. 2002;109(4):437-442. https://doi.org/10.1172/JCI15077. Perspective No one will dispute that death receptors do exactly what their name suggests, induce programmed cell death. In addition, however, several reports have recently suggested that these receptors, or their downstream regulators, may also function in certain aspects of cell growth or differentiation. These claims might be met with justifiable skepticism. Certainly there is nothing more opposite in cell fate than growth and death. Yet the signal pathways used by these two processes appear to commingle, and the eventual outcome of the signaling vector may be bent toward one result over the other by seemingly subtle balances among these components. Here, following a brief review of the traditional signal pathways that lead from death receptor activation to apoptosis, I scrutinize the various reports of increased growth or differentiation mediated by these same receptors. I then consider newly identified signal pathways linked to death receptors that might promote growth and, finally, speculate on whether these events represent merely interesting in vitro manipulations or actual physiologically important processes. Conventional death receptor signaling The classical view of death receptor function is typified by Fas (CD95/APO-1), a member of the TNF receptor (TNFR) family (1). Trimerization, or more likely oligomerization of Fas, leads to formation of the death-inducing signal complex (DISC), starting with recruitment of the Fas-adapter protein FADD through their mutual death domains […] Find the latest version: https://jci.me/15077/pdf PERSPECTIVE SERIES Lymphocyte signal transduction Gary Koretzky, Series Editor Death receptors couple to both cell proliferation and apoptosis Ralph C.
    [Show full text]
  • Distinct Effects of CD30 and Fas Signaling in Cutaneous Anaplastic Lymphomas: a Possible Mechanism for Disease Progression
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Distinct Effects of CD30 and Fas Signaling in Cutaneous Anaplastic Lymphomas: A Possible Mechanism for Disease Progression Edi Levi, Zhenxi Wang, Tina Petrogiannis-Haliotis, Walther M. Pfeifer, Werner Kempf, Reed Drews, and Marshall E. Kadin Departments of Pathology and Medicine, Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, U.S.A. Lymphomatoid papulosis is part of a spectrum of agonistic antibody, HeFi-1. Proliferative responses, CD30+ cutaneous lymphoproliferative disorders char- mitogen-activated protein kinase, and nuclear factor acterized by spontaneous tumor regression. The kB activities were determined with and without CD30 mechanism(s) of regression is unknown. In a recent activation. Mac-1 and Mac-2 A showed increased pro- study, a selective increase in CD30 ligand expression in liferative responses to incubation with CD30 activating regressing lesions of lymphomatoid papulosis and antibody, HeFi-1. Inhibition of the mitogen-activated cutaneous CD30+ anaplastic large cell lymphoma was protein kinase activity caused growth inhibition of the shown, suggesting that activation of the CD30 signal- Mac-1, Mac-2 A, and JK cell lines. Activation of the ing pathway may be responsible for tumor regression, Fas pathway induced apoptosis in all three cell lines. whereas no difference in Fas/Fas ligand expression Taken together, these ®ndings suggest that resistance was found between regressing and nonregressing to CD30-mediated growth inhibition provides a lesions. Therefore we tested the effects of CD30 and possible mechanism for escape of cutaneous anaplastic Fas activation on three CD30+ cutaneous lymphoma large cell lymphoma from tumor regression.
    [Show full text]